These CD4+ responses have proved to be efficient in antitumoral treatments. In fact, in patients with melanoma or glioblastoma, a good response against immunizing peptides favoring CD4+ over CD8+ has been observed, even though these were predicted and prioritized using HLA‐I binding algorithms.[43] The use of antigen presentation via HLA‐II is supported by the facts that the majority of the immunogenic mutanome is recognized by CD4+ T cells and that vaccination with such CD4 T cell‐reactive mutations confers strong antitumor activity.[44]. The gene discussed is CD8A; the disease is melanoma.